Allergic conjunctivitis treatment approved in Japan

Santen Pharmaceutical Co., Ltd. announced that Japan's Ministry of Health, Labor and Welfare has approved Alesion 0.05% Ophthalmic Solution (generic name: epinastine HCl) for treating allergic conjunctivitis.

Japanese clinical trials showed that epinastine HCl, the active ingredient in Alesion 0.05% Ophthalmic Solution, blocks histamine H₁ receptors and inhibits the release of chemical mediators from mast cells, alleviating ocular itching and hyperemia. No ocular or systemic serious adverse drug reactions were observed in these studies.